Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 9/20/2018 |
| Start Date: | September 2009 |
| End Date: | August 2019 |
To test the preliminary efficacy of 16.0 mg of Prazosin daily versus placebo in treatment
seeking alcohol dependent individuals. This proposal is a laboratory and treatment outcome
study to examine the effects of Prazosin on brief exposure to stress, drug cues and neutral
situations on alcohol and drug craving, mood and neurobiological reactivity in a sample of
cocaine and/or alcohol dependent individuals. Prazosin will be beneficial for reduction in
stress and drug cue induced craving and related arousal. In a sample of 120 alcohol dependent
men and women, we propose to examine (a) differences in measures of cocaine craving, emotion
state, hypothalamic-pituitary-adrenal (HPA) activation, physiological arousal and plasma
catecholamine response to stress imagery and to drug cue imagery as compared to neutral
imagery; (b) reduction in alcohol abstinence symptoms; and (c) improvement in alcohol
treatment outcomes as measured by increasing abstinence, reduction in alcohol use, increased
treatment attendance and decreased relapse risk.
seeking alcohol dependent individuals. This proposal is a laboratory and treatment outcome
study to examine the effects of Prazosin on brief exposure to stress, drug cues and neutral
situations on alcohol and drug craving, mood and neurobiological reactivity in a sample of
cocaine and/or alcohol dependent individuals. Prazosin will be beneficial for reduction in
stress and drug cue induced craving and related arousal. In a sample of 120 alcohol dependent
men and women, we propose to examine (a) differences in measures of cocaine craving, emotion
state, hypothalamic-pituitary-adrenal (HPA) activation, physiological arousal and plasma
catecholamine response to stress imagery and to drug cue imagery as compared to neutral
imagery; (b) reduction in alcohol abstinence symptoms; and (c) improvement in alcohol
treatment outcomes as measured by increasing abstinence, reduction in alcohol use, increased
treatment attendance and decreased relapse risk.
Inclusion Criteria:
- Male or female individuals, ages 18-50, meeting current DSM-IV criteria for alcohol
dependence.
- ALCOHOLIC SAMPLE: meet current DSM-IV criteria for alcohol dependence
- COCAINE SAMPLE: meet current DSM-IV criteria for cocaine dependence; documented
positive urine toxicology screen for cocaine at intake
- Subject has voluntarily given informed consent and signed the informed consent
document.
- Able to read English and complete study evaluations.
Exclusion Criteria:
- Meet current criteria for dependence on another psychoactive substance, excluding
nicotine and caffeine;
- Any current use of opiates;
- Current use of any psychoactive drugs, including anxiolytics, antidepressants,
naltrexone or disulfram, except for stabilized on SSRIs
- Any psychotic disorder or current Axis I psychiatric symptoms requiring specific
attention, including need for psychiatric medications for current major depression and
anxiety disorders
- Significant underlying medical conditions such as cerebral, renal, thyroid or cardiac
pathology which in the opinion of study physician would preclude patient from fully
cooperating or be of potential harm during the course of the study;
- Hypotensive individuals with sitting blood pressure below 100/50 mmHG.
We found this trial at
1
site
New Haven, Connecticut 06519
Phone: 203-737-4791
Click here to add this to my saved trials
